Sandoz Group AG (SWX:SDZ)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 24.56B |
| Revenue (ttm) | 8.42B |
| Net Income (ttm) | 180.53M |
| Shares Out | 430.70M |
| EPS (ttm) | 0.42 |
| PE Ratio | 137.12 |
| Forward PE | 19.20 |
| Dividend | 0.60 (1.05%) |
| Ex-Dividend Date | Apr 17, 2025 |
| Volume | 621,359 |
| Average Volume | 718,397 |
| Open | 57.42 |
| Previous Close | 57.02 |
| Day's Range | 57.20 - 58.22 |
| 52-Week Range | 26.25 - 58.22 |
| Beta | 0.26 |
| RSI | 71.87 |
| Earnings Date | Feb 25, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileNews
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Buy: Here's Why
Sandoz Group AG Sponsored ADR (SDZNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term...
SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Sandoz Launches Wyost And Jubbonti In Europe
(RTTNews) - Sandoz (SDZ.SW) announced the European launch of Wyost and Jubbonti. The medicines are among the first denosumab biosimilars to launch in Europe and are approved to treat all indications o...
Sandoz Announces Launch Of TYRUKO In The US
(RTTNews) - Sandoz announced that TYRUKO or natalizumab-sztn is available to patients in the US. Developed by Polpharma Biologics, TYRUKO is the only FDA approved natalizumab biosimilar for the treatm...
Sandoz To Acquire Just-Evotec Biologics EU SAS In Strategic Biosimilars Expansion Deal
(RTTNews) - Sandoz (SDZNY) announced a strategic agreement with Evotec SE to acquire all issued and outstanding equity interests of Just-Evotec Biologics EU SAS (JEB SAS), including its Toulouse-based...
Evotec (EVO) Sells Biologics Site to Sandoz for $350M
Evotec (EVO) Sells Biologics Site to Sandoz for $350M
Evotec signs deal with Sandoz for Just - Evotec Biologics site
SDZNY vs. STVN: Which Stock Is the Better Value Option?
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Sandoz Group AG (SDZNY) Q3 2025 Sales Call Transcript
Sandoz Group AG (SDZNY) Q3 2025 Sales/ Trading Statement Call - Slideshow
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta
Sandoz granted tentative approval for generic of Pfizer's Inlyta
Sandoz gets FDA tentative approval for a generic of Pfizer’s kidney cancer drug Inlyta, but launch is delayed by patent litigation. Read more here.
Regeneron (REGN) Reaches Settlement with Sandoz Over Eylea Biosimilar
Regeneron (REGN) Reaches Settlement with Sandoz Over Eylea Biosimilar
Sandoz welcomes Quebec government support for Boucherville plant modernization project
Sandoz underlines importance of Delpharm Boucherville plant modernization project, made possible by total investment of CAD 220 million Amount includes joint investments from provincial and federal go...
Lupin partners with Sandoz to commercialize Ranibizumab biosimilar in multiple global markets
Lupin Limited announced on August 12 that it has entered into a licensing and commercialization agreement with Switzerland-based Sandoz Group AG for its biosimilar Ranibizumab. The deal covers multipl...
Sandoz Group AG 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Sandoz Group AG in conjunction with their 2025 Q2 earnings call.
Sandoz Group AG (SDZNY) Q2 2025 Earnings Call Transcript
Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next year.
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor
Danish pharma giant Novo Nordisk A/S (NYSE: NVO) faces potential financial losses related to its blockbuster weight-loss and diabetes drug, Ozempic, due to a regulatory issue. What Happened: About a ...
Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript
Sandoz inks agreement with Shanghai Henlius for Bristol Yervoy biosimilar
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ: AMGN) for extending and entrenching the dominant market position of its block...
Amgen faces antitrust lawsuit from Sandoz over Enbrel patents
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept ...
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US | SDZNY Stock News